Patterns of blood product use among patients with myelodysplastic syndrome

Vox Sanguinis

Volumn 102, Issue 4, 2012, Pages 331-337

  Ramsey, S D ^a   Mccune, J S ^b   Blough, D K ^b   Mcdermott, C L ^a   Beck, S J ^a   Lopez J A ^c   Joachim Deeg, H ^a  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c PUGET SOUND BLOOD CENTER   (United States)

Author keywords

Myelodysplastic syndrome; Platelets; Red blood cells; Survival; Transfusion

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; COHORT ANALYSIS; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION;

BLOOD TRANSFUSION; DATABASES, FACTUAL; ERYTHROCYTE TRANSFUSION; HUMANS; MYELODYSPLASTIC SYNDROMES; PLATELET TRANSFUSION; REGISTRIES; SEER PROGRAM;

EID: 84859822491     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2011.01568.x     Document Type: Article

References (17)

1. Malcovati L, Porta MG, Pascutto C, et al. : Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23:7594-7603
2. Balducci L: Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer 2006; 106:2087-2094
3. Armand P, Kim HT, Cutler CS, et al. : Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109:4586-4588
4. Takatoku M, Uchiyama T, Okamoto S, et al. : Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007; 78:487-494
5. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. : Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28:562-569
6. Kantarjian H, Issa JP, Rosenfeld CS, et al. : Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106:1794-1803
7. Raza A, Reeves JA, Feldman EJ, et al. : Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008; 111:86-93
8. Puget Sound Cancer Surveillance System. CSS reports, publications, and FAQs. 2010. Available from: (last accessed: December 10, 2010)
9. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: myelodysplastic syndrome, v.2.2010. 2010. Available from: (last accessed: December 10, 2010)
10. Goldberg SL, Chen E, Corral M, et al. : Incidence and clinical complications of myelodysplastic syndromes among United States medicare beneficiaries. J Clin Oncol 2010; 28:2847-2852
11. Santini V, Alessandrino PE, Angelucci E, et al. : Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res 2010; 34:1576-1588
12. Fenaux P, Gattermann N, Seymour JF, et al. : Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 2010; 149:244-249
13. Malcovati L, Germing U, Kuendgen A, et al. : Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25:3503-3510
14. Delea TE, Hagiwara M, Phatak PD: Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin 2009; 25:139-147
15. Raptis A, Duh MS, Wang ST, et al. : Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. Transfusion 2010; 50:190-199
16. Fisher ES, Whaley FS, Krushat WM, et al. : The accuracy of medicare's hospital claims data: progress has been made, but problems remain. Am J Public Health 1992; 82:243-248
17. De Roos AJ, Deeg HJ, Davis S: A population-based study of survival in patients with secondary myelodysplastic syndromes (MDS): impact of type and treatment of primary cancers. Cancer Causes Control 2007; 18:1199-1208